Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BeiGene, Ltd.
< Previous
1
2
Next >
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 19, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
September 19, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
August 02, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
May 30, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
May 04, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports Second Quarter 2022 Financial Results
August 04, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
May 17, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports First Quarter 2022 Financial Results
May 05, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Introduces Global Environmental, Social, and Governance Strategy
April 26, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
April 11, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
February 08, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
January 06, 2022
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
December 20, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
December 14, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
December 02, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
November 30, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
November 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
November 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports Third Quarter 2021 Financial Results
November 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Inclusion in FTSE Russell Indices
September 20, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
September 15, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
September 13, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
September 12, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
September 01, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
August 22, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
August 17, 2021
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.